-
1 Comment
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the sector with a price to sales ratio of 0.0.
Based on the above factors, InspireMD, Inc gets an overall score of 1/5.
| Industry | |
|---|---|
| Sector | |
| ISIN | None |
| CurrencyCode | USD |
| Exchange | NASDAQ |
| Beta | 1.86 |
|---|---|
| Market Cap | 41M |
| Target Price | None |
| PE Ratio | None |
| Dividend Yield | None |
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard, a neurovascular flow diverter that diverts blood flow away from cerebral aneurysms and seals the aneurysms. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv, Israel.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for NSPRZ using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
